Erdafitinib (** Balversa® (brand name) / Erdafitinib (generic) **)

Targeted Therapy

EU Not submitted to EMA ES Not available 2 Clinical Trials

Description

Erdafitinib is used in the treatment of advanced or metastatic urothelial carcinoma with FGFR alterations. It has shown efficacy in clinical trials for patients who have progressed on or are intolerant to platinum-containing chemotherapy and have an FGFR genetic alteration. Erdafitinib is not currently approved by the FDA specifically for colorectal cancer, but it is under investigation for other solid tumors.

Mechanism of Action

Erdafitinib is a small molecule inhibitor of FGFR1-4, which blocks the activation and dimerization of fibroblast growth factor receptors (FGFRs), thereby inhibiting downstream signaling pathways such as MAPK/ERK and PI3K/AKT/mTOR that are involved in cell proliferation and survival.

Side Effects

Hyperphosphatemia; Hypertension; Dry eye syndrome; Increased creatinine; QT interval prolongation

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03155620 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
United States, Australia, Canada, Puerto Rico
NCT02465060 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
United States, Guam, Puerto Rico

Quick Info

Brand Name** Balversa® (brand name) / Erdafitinib (generic) **
CategoryTargeted Therapy
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Regorafenib
Targeted Therapy
108 trials
Rego
Targeted Therapy
108 trials
Fruquintinib
Targeted Therapy
59 trials
Encorafenib
Targeted Therapy
26 trials
Binimetinib
Targeted Therapy
22 trials
Trametinib
Targeted Therapy
22 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.